



Epigenomics in Prostate Cancer

Guest Editor:

Dr. Antoinette S. Perry

Cancer Biology and Therapeutics
Laboratory, UCD Conway
Institute of Biomolecular and
Biomedical Research, University
College Dublin, Dublin, Ireland
School of Biology and
Environmental Science,
University College Dublin, Dublin,
Ireland

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editor

Dear Colleagues,

Prostate cancer is one of the most common male malignancies in the world. It displays a high incidence to mortality ratio, meaning that the majority of men experience a relatively low-risk, latent form of the disease. However, a proportion of tumours have an aggressive nature and hence prostate cancer is the 5th leading cause of cancer-related deaths in men worldwide. The fact that prostate cancer displays an atypically low mutation rate, has undoubtedly contributed to our lack of clarity on hallmark molecular features of aggressive and indolent disease. By contrast, epigenetic alterations are frequent during prostate cancer initiation and progression and indeed the disease is known to undergo an epigenetic catastrophe during the earliest stages of tumour development, with widespread promoter hypermethylation and silencing of regulatory genes.

This special issue will highlight the central, yet complex, role that epigenomics plays in prostate cancer, from disease development through to castration resistance, and the utility that it offers in disease detection, stratification and prognostication.

Dr. Antoinette S. Perry
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)